Skip to main content
. Author manuscript; available in PMC: 2022 Aug 10.
Published in final edited form as: Nature. 2022 Feb 9;602(7897):518–522. doi: 10.1038/s41586-021-04393-3

Extended Data Fig. 9. Kaplan-Meier estimates of overall survival in glioblastoma patients with different EGFR status from the TCGA database.

Extended Data Fig. 9.

Two-sided log-rank tests were performed to assess the overall survival differences between different patient groups, with no corrections made for multiple pairwise comparisons. Patients with no EGFR alteration (n = 322 patients; red line) had median overall survival times of 14.4 months (95% CI, 12.7-15.8), which was not statistically significantly different from:

a. Patients with any EGFR alteration (n = 270 patients; blue dashed line), who had median overall survival times of 14.3 months (95% CI, 13.3-15.6), p = 0.06.

b. Patients with an EGFR mutation (n = 22 patients; blue dashed line), who had median overall survival times of 15.9 months (95% CI, 11.3-23.2), p = 0.6.

c. Patients with an EGFR mutation and EGFR amplification (n = 58 patients; blue dashed line), who had median overall survival times of 13.9 months (95% CI, 11.2-17.5), p = 0.66.

d. Patients with EGFR amplification (n = 85 patients; blue dashed line), who had median overall survival times of 14.3 months (95% CI, 11.8-16.8), p = 0.28.